Biotech Values

[DewDiligence]

QURE -11% on 3Q15 results/timing of HBV data:

http://finance.yahoo.com/news/uniqure-announces-financial-results-third-123000997.html

Hemophilia B Program Update

• The first cohort of five hemophilia B patients has been dosed in the Phase 1/2 study of AMT-060.

• In early January 2016, the Company plans to release preliminary, top-line data for the two patients who will have completed at least 12 weeks of treatment follow-up. The data readout will include safety results and FIX expression levels. No additional data from the remaining cohort patients or other measures of the trial will be reported at that time.

• The Company expects to report on the full results of the first cohort at a scientific conference during 1H 2016.

I don’t know how this compares to prior guidance for the reporting of data from the HBV trial.